<DOC>
	<DOCNO>NCT01332604</DOCNO>
	<brief_summary>This open-label , multicenter , Phase Ib , dose-escalation study design assess safety , tolerability , pharmacokinetics oral GDC-0980 administer combination capecitabine mFOLFOX6 chemotherapy bevacizumab add Cycle 5 patient advanced metastatic solid tumor .</brief_summary>
	<brief_title>GDC-0980 Combination With Fluoropyrimidine , Oxaliplatin , Bevacizumab Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically cytologically document locally advanced metastatic solid tumor establish therapy ineffective , tolerable , exist Patients histologically cytologically document locally advanced metastatic breast cancer receive least one prior chemotherapybased regimen incurable disease ( Arm A ) Patients histologically cytologically document locally advanced metastatic CRC receive prior oxaliplatinbased therapy within 1 year initiation study treatment . ( Arm B ) Prior anticancer therapy fulfill follow criterion : total six course alkylating agent , total four course carboplatincontaining chemotherapy regimen , total two course nitrosoureas mitomycin C , highdose chemotherapy require stemcell support , irradiation &gt; = 25 % bone marrowbearing area Current dyspnea rest complication advance malignancy disease require continuous oxygen therapy Known deficiency dihydropyrimidine dehydrogenase ( DPD ) Bisphosphonate therapy symptomatic hypercalcemia Known untreated active central nervous system ( CNS ) metastases Pregnancy , lactation , breastfeed For Arm B : Inadequately control hypertension Prior history hypertensive crisis hypertensive encephalopathy History myocardial infarction unstable angina within 6 month prior first dose study treatment History stroke transient ischemic attack within 6 month prior first dose study treatment Significant vascular disease within 6 month prior first dose study treatment History hemoptysis within 1 month prior first dose study treatment Patients one pulmonary tumor mass evidence cavitation Evidence bleed diathesis significant coagulopathy Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior first dose study treatment History abdominal fistula , GI perforation , intraabdominal abscess within 6 month prior first dose study treatment Clinical sign symptom GI obstruction requirement parenteral hydration , parenteral nutrition , tube feed Evidence abdominal free air explain paracentesis recent surgical procedure Serious , nonhealing wound , active ulcer , untreated bone fracture The presence ulcerating breast cancer tumor render patient ineligible Proteinuria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>